Difference between revisions of "Hals 2013 J Diabetes Res"
Bader Helga (talk | contribs) |
Bader Helga (talk | contribs) |
||
| Line 5: | Line 5: | ||
|year=2013 | |year=2013 | ||
|journal=J Diabetes Res | |journal=J Diabetes Res | ||
|abstract=Islet transplantation in diabetes is hampered by the need of life-long immunosuppression. Encapsulation provides partial immunoprotection but could possibly limit oxygen supply, a factor that may enhance hypoxia-induced beta cell death in the early post-transplantation period. Here we tested susceptibility of alginate microencapsulated human islets to experimental hypoxia (0.1-0.3 % O2 for 8 h, followed by re-oxygenation) on viability and functional parameters. Hypoxia reduced viability as measured by MTT by 33.8 ± 3.5 % in encapsulated and 42.9 ± 5.2 % in non-encapsulated islets (p < 0.2). Non-encapsulated islets released 37.7% (median) more HMGB1 compared to encapsulated islets after hypoxic culture conditions (p < 0.001). Glucose-induced insulin release was marginally affected by hypoxia. Basal oxygen consumption was equally reduced in encapsulated and non-encapsulated islets, by 22.0 ± 6.1 % vs. 24.8 ± 5.7 %. Among 27 tested cytokines/chemokines, hypoxia increased the secretion of IL-6 and IL-8/CXCL8 in both groups of islets whereas an increase of MCP-1/CCL2 was seen only with non-encapsulated islets. Conclusion: alginate microencapsulation of human islets does not increase susceptibility to acute hypoxia. This is a positive finding in relation to potential use of encapsulation for islet transplantation. | |abstract=Islet transplantation in diabetes is hampered by the need of life-long immunosuppression. Encapsulation provides partial immunoprotection but could possibly limit oxygen supply, a factor that may enhance hypoxia-induced beta cell death in the early post-transplantation period. Here we tested susceptibility of alginate microencapsulated human islets to experimental hypoxia (0.1-0.3 % O2 for 8 h, followed by re-oxygenation) on viability and functional parameters. Hypoxia reduced viability as measured by MTT by 33.8 ± 3.5 % in encapsulated and 42.9 ± 5.2 % in non-encapsulated islets (''p'' < 0.2). Non-encapsulated islets released 37.7% (median) more HMGB1 compared to encapsulated islets after hypoxic culture conditions (''p'' < 0.001). Glucose-induced insulin release was marginally affected by hypoxia. Basal oxygen consumption was equally reduced in encapsulated and non-encapsulated islets, by 22.0 ± 6.1 % vs. 24.8 ± 5.7 %. Among 27 tested cytokines/chemokines, hypoxia increased the secretion of IL-6 and IL-8/CXCL8 in both groups of islets whereas an increase of MCP-1/CCL2 was seen only with non-encapsulated islets. Conclusion: alginate microencapsulation of human islets does not increase susceptibility to acute hypoxia. This is a positive finding in relation to potential use of encapsulation for islet transplantation. | ||
|keywords=Human islets, | |keywords=Human islets, Microencapsulation, Hypoxia, Viability, Oxygen consumption, Insulin release, Cytokine/chemokine secretion | ||
|mipnetlab=NO Trondheim Grill V | |mipnetlab=NO Trondheim Grill V | ||
}} | }} | ||
Revision as of 12:45, 5 March 2015
| Hals IK, Rokstad AM, Strand BL, Oberholzer J, Grill V (2013) Alginate microencapsulation of human islets does not increase susceptibility to acute hypoxia. J Diabetes Res 2013:374925. |
Hals IK, Rokstad AM, Strand BL, Oberholzer J, Grill V (2013) J Diabetes Res
Abstract: Islet transplantation in diabetes is hampered by the need of life-long immunosuppression. Encapsulation provides partial immunoprotection but could possibly limit oxygen supply, a factor that may enhance hypoxia-induced beta cell death in the early post-transplantation period. Here we tested susceptibility of alginate microencapsulated human islets to experimental hypoxia (0.1-0.3 % O2 for 8 h, followed by re-oxygenation) on viability and functional parameters. Hypoxia reduced viability as measured by MTT by 33.8 ± 3.5 % in encapsulated and 42.9 ± 5.2 % in non-encapsulated islets (p < 0.2). Non-encapsulated islets released 37.7% (median) more HMGB1 compared to encapsulated islets after hypoxic culture conditions (p < 0.001). Glucose-induced insulin release was marginally affected by hypoxia. Basal oxygen consumption was equally reduced in encapsulated and non-encapsulated islets, by 22.0 ± 6.1 % vs. 24.8 ± 5.7 %. Among 27 tested cytokines/chemokines, hypoxia increased the secretion of IL-6 and IL-8/CXCL8 in both groups of islets whereas an increase of MCP-1/CCL2 was seen only with non-encapsulated islets. Conclusion: alginate microencapsulation of human islets does not increase susceptibility to acute hypoxia. This is a positive finding in relation to potential use of encapsulation for islet transplantation. • Keywords: Human islets, Microencapsulation, Hypoxia, Viability, Oxygen consumption, Insulin release, Cytokine/chemokine secretion
• O2k-Network Lab: NO Trondheim Grill V
Labels: MiParea: Respiration, mt-Medicine
Stress:Hypoxia Organism: Human Tissue;cell: Islet cell;pancreas;thymus Preparation: Intact cells
Coupling state: ROUTINE, ETS"ETS" is not in the list (LEAK, ROUTINE, OXPHOS, ET) of allowed values for the "Coupling states" property.
HRR: Oxygraph-2k
